MMED vs MRNA: fair value comparison
MiniMed Group, Inc. and Moderna, Inc. · Updated 2026-10-19
MMED's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. MRNA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MMED currently ranks higher by quality score.
| MMED | MRNA | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $17.49 | $218.01 |
| 12-month range | $12.00–$22.42 | $22.36–$236.50 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #196 of 301 Healthcare | #197 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: MMED fair value analysis · MRNA fair value analysis